论文部分内容阅读
上海市医药管理局于82年12月28日在沪召开治疗冠心病的新颖中成药麝香保心丸鉴定会。麝香保心丸是上海市经委新产品科研项目。由上海中药制药一厂和上海第一医学院附属华山医院共同研制成功的。会议听取了麝香保心丸科研工作总结和鉴别试验、药理毒理、工艺、质量标准、临床验证等报告,经上海中山医院等八家市级医院209个心脏病(344例次)的临床验证,证明麝香保心丸对冠心病人的心绞痛、胸闷和心肌梗塞
The Shanghai Municipal Pharmaceutical Administration held the appraisal meeting of Xinxiang Yaoxin Baoxin Pill for the treatment of coronary heart disease on December 28, 82 in Shanghai. Shexiang Baoxin Pill is a new product research project of Shanghai Economic Commission. It was jointly developed by Shanghai No.1 Pharmaceutical Factory and Huashan Hospital Affiliated to Shanghai First Medical College. The meeting heard reports on the scientific work summary and identification tests, pharmacology and toxicology, techniques, quality standards, and clinical verification reports of Ruan Baoxin Baoxin Pills. Clinical validation of 209 heart diseases (344 cases) in eight municipal hospitals such as Shanghai Zhongshan Hospital. , To prove that Shexiang Baoxin Pill treats coronary heart disease with angina, chest tightness and myocardial infarction